Imanishi Naoko
   Department   University Hospital  General Thoracic Surgery, Clinical Departments
   Position  
Article types case reports
Language English
Peer review Peer reviewed
Title Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.
Journal Formal name:Journal of surgical oncology
Abbreviation:J Surg Oncol.
ISSN code:1096-9098
Domestic / ForeginForegin
Volume, Issue, Page 0(0),0-0頁
Author and coauthor Imanishi N, Hirai A, Yoneda K, Shimajiri S, Kuwata T, Tashima Y, Takeuchi M, Iwai Y, Ichiki Y, Tanaka F.
Publication date 2018/03
Summary Abstract
BACKGROUND AND OBJECTIVES:
Pulmonary pleomorphic carcinoma (PPC) is a rare and aggressive subtype of lung cancer. Programmed cell death-ligand 1 (PD-L1) expression may be induced in a variety of malignant tumors, but its prognostic implication in PPC remains unclear.
METHODS:
Twenty-six patients with surgically resected PPC were retrospectively reviewed. Immuno-histochemical staining was used to detect PD-L1 expression, and PD-L1 status was classified into "high" or "low" according to the percentage of tumor cells (TCs) expressing PD-L1 (tumor proportion score, TPS).
RESULTS:
PD-L1 expression was positive in 20 (76.9%) patients at the cut-off TPS value of 1%. A receiver-operating characteristic (ROC) analysis showed that the optimal cut-off value was 15% for prediction of cancer-specific death with the area under ROC curve of 0.701 (P = 0.107). High PD-L1 expression was associated with a favorable overall survival (100% vs 45.9% at 5 years; P = 0.046) as well as a favorable cancer-specific survival (88.9% vs 37.5% at 5 years; P = 0.012). A multivariate analysis indicated a trend toward a favorable prognosis associated with high PD-L1 expression (hazard ratio [HR], 0.254 [95% confidence interval, 0.054-1.200]; P = 0.084).
DOI 10.1002/jso.25041
PMID 29601633